Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price ...
Erdafitinib showed a predictable toxicity profile and early efficacy in IDH–wild-type glioma with FGFR-TACC fusions. The recommended phase 2 dose was 8 mg daily, with one grade 3 central serous ...
Climate Compass on MSN
CRISPR and the future: Can we edit out genetic diseases?
We're living in a moment where science fiction is becoming medical reality. Imagine a world where doctors can simply rewrite ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback